Meta-analysis comparing cisplatin total dose intensity and survival

Area of Science:

• Oncology
• Clinical Pharmacology
• Cancer Research

Background:

• Ovarian cancer remains a significant health challenge, particularly in advanced stages (III-IV).
• Chemotherapy dosing strategies, including dose intensity, are critical in optimizing treatment outcomes.
• Understanding the relationship between chemotherapy dose intensity and patient survival is essential for treatment refinement.

Purpose of the Study:

• To investigate the association between total dose intensity (TDI) of cisplatin/carboplatin, overall chemotherapy drug intensity (GDI), and median survival (MS).
• To determine the prognostic significance of chemotherapy dose intensity and optimal debulking in stage III-IV ovarian cancer.

Main Methods:

• A systematic review and meta-analysis of over 700 English literature studies.
• Inclusion criteria: prospective clinical trials with cisplatin/carboplatin, data on MS, and chemotherapy dose/schedule.
• Calculation of dose intensity (DI), TDI, and GDI; linear regression models used to assess relationships with MS.

Main Results:

• Analysis of 61 study arms (4118 patients) revealed no significant correlation between DI or TDI of cisplatin/carboplatin and MS.
• Proportion of optimally debulked patients (%OD) and GDI showed a significant correlation with MS.
• Studies with GDI < 20 and %OD < 20% had MS < 20 months; conversely, GDI > 20 and %OD > 20% correlated with MS > 20 months in 77% of studies.

Conclusions:

• Overall chemotherapy drug intensity (GDI) and the proportion of optimally debulked patients (%OD) are key determinants of median survival in advanced ovarian cancer.
• Cisplatin/carboplatin dose intensity alone does not appear to be a significant predictor of survival in this patient population.
• Treatment strategies should consider comprehensive chemotherapy dosing and surgical debulking for improved patient outcomes.